Recombinant Human Inositol Monophosphatase 2 IMPA2
- Known as:
- Recombinant Human Inositol Monophosphatase 2 IMPA2
- Catalog number:
- enz-070
- Product Quantity:
- 2
- Category:
- -
- Supplier:
- Prospecbio
- Gene target:
- Recombinant Human Inositol Monophosphatase 2 IMPA2
Related genes to: Recombinant Human Inositol Monophosphatase 2 IMPA2
- Gene:
- IMPA2 NIH gene
- Name:
- inositol monophosphatase 2
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 18p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1997-08-18
- Date modifiied:
- 2016-10-05
Related products to: Recombinant Human Inositol Monophosphatase 2 IMPA2
Related articles to: Recombinant Human Inositol Monophosphatase 2 IMPA2
- Sunitinib serves as the primary treatment for clear cell renal cell carcinoma (ccRCC). However, patients frequently develop resistance to it over time. Early prediction of sunitinib resistance and ccRCC prognosis is beneficial for optimizing clinical treatment. Therefore, we aimed to identify key genes associated with ccRCC sunitinib resistance and prognosis and develop a Clinical Gene Prognostic Nomogram Model (CGPNM) to assess drug sensitivity, treatment response, and survival outcomes in patient groups stratified by CGPNM nomogram scores. - Source: PubMed
Publication date: 2026/04/22
Wang JieDong JunKang LongSun LinsuXie XinlanLu XiMeng YuanyuanTan XinyiSun TaoWang Jian - Alzheimer's disease and related dementias (ADRD) and Parkinson's disease and related disorders (PDRD) have substantial genetic contributions, yet the role of rare damaging coding variants remains incompletely characterized at population scale. We performed gene-based burden testing of rare loss-of-function and deleterious missense variants using whole-genome sequencing data from large population biobanks combined with disease-specific sequencing cohorts, leveraging proxy phenotypes to maximize statistical power for late-onset neurodegenerative diseases. We confirmed rare variant burden in established ADRD genes () and PDRD genes (). We additionally identified novel associations in ADRD () and PDRD (). The strongest signal was observed for , where damaging variants clustered within domains mediating interactions with Rab GTPases and retromer components. Our results demonstrate the power of population-scale sequencing combined with proxy phenotypes to identify rare coding risk genes for neurodegenerative diseases. - Source: PubMed
Publication date: 2026/03/04
Le Guen YannPeña-Tauber AndrésPulgrossi Rafael CatoiaPark JunyoungOrias HoldenGreicius Michael D - Cervical cancer (CC) poses a significant health risk for women. Our previous studies have found that IMPA2 is an oncogene in CC and is associated with apoptosis; however, the exact regulatory mechanism is not clear. - Source: PubMed
Publication date: 2025/12/22
Wu XinyiWang BingqiLiu LeiChen ZhenniWang Min - Wilms' tumor (WT) and rhabdoid tumor (RT) are the predominant renal neoplasms in pediatric patients, and their metastatic potential significantly impacts the prognosis of affected children. However, limited research has been conducted on elucidating the underlying molecular mechanisms driving metastasis in these tumors, resulting in a dearth of well-defined molecular targets. Based on the clinical staging information available in the TARGET database for WT and RT, we investigated the differential gene expression profiles and associated molecular pathways implicated in metastasis. Interestingly, our analysis revealed that WT and RT tumor metastases shared a highly expressed gene IMPA2, which was associated with poor prognosis. Additionally, experimental validation confirmed that IMPA2 exerted regulatory effects on the Wnt signaling pathway as well as N-cadherin and E-cadherin levels, thereby influencing the migratory and invasive capabilities of G401 cells. Moreover, gene profiles and molecular pathways associated with IMPA2 expression were comprehensively analyzed, transcription factors potentially regulating IMPA2 were identified, and correlations with immune-related genes were determined. Regarding therapy, we identified small molecule drugs that affected IMPA2 expression and utilized molecular docking to predict their direct binding to the IMPA2 protein. These findings have provided biomarkers and therapeutic targets for the metastatic WT and RT, while the investigated targeted drugs hold promise as novel therapeutic strategies to enhance the prognosis of affected children. - Source: PubMed
Publication date: 2025/10/27
Li ShuxianYan JunZhang XueXiao ZhaohuaMu NingSha GuomengZhang WenhaoZhou YongjiaWang ZunzheZhang YiweiLi Lingbing - Emerging clinical evidence has linked inositol levels to clinical features in lower-grade glioma (LGG). However, the architecture and functional significance of inositol metabolism remain poorly defined. - Source: PubMed
Publication date: 2025/10/13
Chen QianDeng DongfengShen LiangfangLi Shan